Complete financial analysis of GENinCode plc (GENI.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GENinCode plc, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Shanghai Shenda Co., Ltd (600626.SS) Income Statement Analysis – Financial Results
- Kjell Group AB (publ) (KJELL.ST) Income Statement Analysis – Financial Results
- Attendo AB (publ) (ATT.ST) Income Statement Analysis – Financial Results
- Shenzhen EXC-LED Technology Co.Ltd (300889.SZ) Income Statement Analysis – Financial Results
- EOS International, Inc. (EOSI) Income Statement Analysis – Financial Results
GENinCode plc (GENI.L)
About GENinCode plc
GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 2.16M | 1.43M | 1.15M | 960.80K | 1.92M |
| Cost of Revenue | 1.14M | 798.00K | 561.00K | 437.79K | 882.23K |
| Gross Profit | 1.02M | 632.00K | 593.00K | 523.02K | 1.04M |
| Gross Profit Ratio | 47.31% | 44.20% | 51.39% | 54.44% | 54.10% |
| Research & Development | 334.00K | 72.00K | 1.00K | 0.00 | 0.00 |
| General & Administrative | 7.75M | 6.27M | 2.01M | 1.57M | 204.84K |
| Selling & Marketing | 71.00K | 145.00K | 134.00K | 79.00K | 1.33M |
| SG&A | 7.82M | 6.27M | 2.14M | 1.57M | 1.54M |
| Other Expenses | 17.00K | 265.00K | 1.99M | 0.00 | 0.00 |
| Operating Expenses | 8.17M | 6.53M | 4.13M | 1.57M | 1.54M |
| Cost & Expenses | 9.31M | 7.33M | 4.69M | 2.01M | 2.42M |
| Interest Income | 174.00K | 160.00K | 8.00K | 67.00 | 0.00 |
| Interest Expense | 48.00K | 14.00K | 0.00 | 8.20K | 7.97K |
| Depreciation & Amortization | 351.00K | 163.00K | 35.00K | 22.77K | 21.16K |
| EBITDA | -6.65M | -5.57M | -4.10M | -1.03M | -483.43K |
| EBITDA Ratio | -307.78% | -389.44% | -250.17% | -107.76% | -24.78% |
| Operating Income | -7.15M | -5.90M | -3.53M | -1.05M | -497.42K |
| Operating Income Ratio | -331.06% | -412.52% | -306.24% | -109.28% | -25.88% |
| Total Other Income/Expenses | 128.00K | 153.00K | 10.00K | 0.00 | -15.15K |
| Income Before Tax | -7.02M | -5.75M | -4.14M | -1.06M | -512.57K |
| Income Before Tax Ratio | -325.14% | -401.82% | -358.41% | -110.13% | -26.67% |
| Income Tax Expense | -7.00K | -187.00K | 6.00K | 8.50K | -108.84K |
| Net Income | -7.02M | -5.56M | -4.14M | -1.07M | -403.73K |
| Net Income Ratio | -324.81% | -388.74% | -358.93% | -111.02% | -21.01% |
| EPS | -0.07 | -0.06 | -0.08 | -9.33 | -6.03 |
| EPS Diluted | -0.07 | -0.06 | -0.08 | -9.33 | -6.03 |
| Weighted Avg Shares Out | 95.82M | 95.82M | 50.55M | 114.36M | 66.96K |
| Weighted Avg Shares Out (Dil) | 95.82M | 95.82M | 50.52M | 114.36M | 66.96K |
Source: https://incomestatements.info
Category: Stock Reports